Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway
Frontiers in Pharmacology · 30.06.2026 · 17
DOI: 10.3389/fphar.2026.1864031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.06.2026. Verfasst von Huaning Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), a key enzyme in cholesterol metabolism, remains underexplored in meningioma. Additionally, the therapeutic potential of Brusatol (Bru), a triterpene lactone compound with anticancer properties, has yet to be systematically evaluated. This research investigates Bru’s efficacy in meningioma treatment and HMGCR-related mechanisms.
Methods
IC 50 was determined using CCK-8 assay. Proliferation, apoptosis, migration, and invasion were assessed through colony formation, EdU, Annexin V/PI staining, Scratch, and Transwell assays, respectively. Cholesterol levels were measured with an assay kit and Filipin III probes. Key pathways and potential meningioma-specific marker were identified via multi-omics with GO/KEGG analyses and bioinformatic analyses. Protein expression was detected via Western blot analysis, and a mouse model of meningioma was employed to evaluate the efficacy of Bru.
Results
Bru inhibited the proliferation, migration, and invasion of meningioma cells, induced apoptosis, and reduced cholesterol accumulation. Proteomic, transcriptomic, and bioinformatic analyses, along with molecular docking, revealed that Bru targeted HMGCR to restrict cholesterol biosynthesis and inhibit the PI3K/AKT signalling pathway. These findings were validated through a series of experiments, including surface plasmon resonance assay, HMGCR knockdown and overexpression, and rescue experiments where HMGCR knockdown or Bru treatment was reversed with an Akt activator SC79. In vivo experiments indicated that Bru effectively suppresses tumour progression, with no significant toxicity observed under the current experimental conditions.
Conclusion
These findings demonstrate that Brusatol suppresses meningioma progression by inhibiting of HMGCR and the PI3K/AKT signaling pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Institute for Brain Tumors, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Jiangsu Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China.
- Department of Neurosurgery, Jiangsu Province (Suqian) Hospital, Suqian, China.
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
- School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Xie, W., Cheng, X., Shen, W., Shi, R., Shi, Z., Wang, Z., Gao, Y., Wang, X., Guo, M., & You, Y. (2026). Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1864031
Vancouver
Li H, Xie W, Cheng X, Shen W, Shi R, Shi Z, et al. Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1864031
BibTeX
@article{Li2026,
author = {Li, Huaning and Xie, Wei and Cheng, Xing and Shen, Wen and Shi, Run and Shi, Zhumei and Wang, Zhichao and Gao, Yu and Wang, Xiefeng and Guo, Mengjie and You, Yongping},
title = {Brusatol suppresses meningioma progression via targeting HMGCR to restrict the cholesterol biosynthesis and inhibit PI3K/AKT signaling pathway},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1864031}
}
EUVIMED